Get the Stockscreener App
3.84
1.03%
-0.04
After Hours:
3.79
-0.05
-1.30%
Perspective Therapeutics Inc stock is traded at $3.84, with a volume of 690.72K.
It is down -1.03% in the last 24 hours and up +11.63% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.88
Open:
$3.88
24h Volume:
690.72K
Relative Volume:
0.62
Market Cap:
$285.04M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-22.38
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
-7.47%
1M Performance:
+11.63%
6M Performance:
+8.17%
1Y Performance:
-71.76%
1-Day Range:
$3.75
$3.96
1-Week Range:
$3.75
$4.28
52-Week Range:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.84 | 288.01M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
How strong is Perspective Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
What makes Perspective Therapeutics Inc. stock price move sharplyFree Investment Playbook for Growing Markets - Newser
Perspective Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowAI Driven Buy Alert Trade Blueprint Released - metal.it
Applying chart zones and confluence areas to Perspective Therapeutics Inc.Investment Timing Strategy with Market Filters - Newser
Volume spikes in Perspective Therapeutics Inc. stock – what they meanSector Rotation Outlook With Historical Summary - Newser
How to read the order book for Perspective Therapeutics Inc.Daily Market Movers Screener with Filters - Newser
Is Perspective Therapeutics Inc. the Top Chart Pick This WeekCommunity Strategy With High Win Rate Backtested - metal.it
How volatile is Perspective Therapeutics Inc. stock compared to the marketFinancial News Outlook For 2025 - jammulinksnews.com
Is it the right time to buy Perspective Therapeutics Inc. stockAI Powered Target Finder For Consistent Profits - jammulinksnews.com
When is Perspective Therapeutics Inc. stock expected to show significant growthDaily Trading Opportunities For Consistent Profits - jammulinksnews.com
Why is Perspective Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough investment performance - jammulinksnews.com
Volume spikes in Perspective Therapeutics Inc. stock – what they mean Asset Growth Pattern and Return Summary - Newser
How many analysts rate Perspective Therapeutics Inc. as a “Buy”High-impact stock picks - jammulinksnews.com
What are the latest earnings results for Perspective Therapeutics Inc.Achieve breakthrough gains with expert advice - jammulinksnews.com
What is the risk reward ratio of investing in Perspective Therapeutics Inc. stockInvest with confidence backed by data - jammulinksnews.com
Perspective Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Predictions - Newser
Moving Average Trends for Perspective Therapeutics Inc. Stock: What They IndicateSmart High Yield Swing Trades - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
What analysts say about Perspective Therapeutics Inc. stockTriple returns potential - PrintWeekIndia
What drives Perspective Therapeutics Inc. stock priceBreakthrough financial growth - PrintWeekIndia
Is Perspective Therapeutics Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Should I buy Perspective Therapeutics Inc. stock before earningsOutstanding capital returns - jammulinksnews.com
What institutions are buying Perspective Therapeutics Inc. stock nowConsistent high-yield stocks - jammulinksnews.com
Perspective Therapeutics Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
Will Perspective Therapeutics Inc. stock benefit from interest rate changesHigh-yield trading alerts - jammulinksnews.com
Perspective Therapeutics to present updated data on cancer therapy at ESMO - Investing.com Canada
Perspective Therapeutics to present updated data on cancer therapy at ESMO By Investing.com - Investing.com South Africa
Perspective Therapeutics Announces Acceptance of VMT-?-NET Data for Presentation at the ESMO Congress 2025 | CATX Stock News - GuruFocus
Perspective Therapeutics, Inc. Announces Acceptance of Updated Data for [212Pb]VMT-α-NET Program at ESMO Congress 2025 - Nasdaq
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 - The Globe and Mail
Major Breakthrough: Phase 2 NET Cancer Treatment Shows Mature Safety Data in 44 Patients, ESMO Preview - Stock Titan
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - MarketScreener
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Cap:
|
Volume (24h):